Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

NCT06984952 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2025-09-05

No results posted yet for this study

Summary

This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients who meet standardized discharge criteria following minimally-invasive gastrectomy.

Conditions

  • Enhanced Recovery After Surgery
  • Gastrectomy for Gastric Cancer

Interventions

PROCEDURE

ERAS protocol

The ERAS protocol includes pre-admission patient education through audiovisual materials; reduction of perioperative fasting duration with preoperative carbohydrate loading and early postoperative oral intake; multimodal prophylaxis for postoperative nausea and vomiting; early removal of surgical drains and intravenous lines; early mobilization; and multimodal analgesia aimed at minimizing postoperative opioid use. The detailed protocol used in this study has been published previously \[https://doi.org/10.5230/jgc.2025.25.e27\].

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER
  • Seoul National University Boramae Hospital

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • Chungnam National University Hospital

    collaborator OTHER
  • Keimyung University Dongsan Medical Center

    collaborator OTHER
  • National Cancer Center, Korea

    collaborator OTHER_GOV
  • The Catholic University of Korea

    collaborator OTHER
  • Ajou University School of Medicine

    collaborator OTHER
  • Pusan National University Hospital

    collaborator OTHER
  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Do Joong Park, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-13
Primary Completion
2028-12-31
Completion
2029-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06984952 on ClinicalTrials.gov